An interventional study of Spectra WaveWriter SCS System in Chronic Pain and Back Pain, sponsored by Boston Scientific Corporation. Completed at 15 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2021-04-01.
Sponsored by Boston Scientific Corporation · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Chronic Pain by Boston Scientific Corporation — 3 open to participants now, 7 under way, none of them phase 3. Chronic Pain · Boston Scientific Corporation.
Among the 37 studies in Chronic Pain by Boston Scientific Corporation, this one is the 12th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2018, is one of 28 with no phase, and was the 23rd registered.
3,228 studies on the registry are indexed under Chronic Pain; 727 are open to participants now.
Browse Chronic Pain studies →3 of the 37 studies in Chronic Pain by Boston Scientific Corporation are open now, in 12 countries. Recruiting first, the newest first:
Boston Scientific Corporation · Sites in United States
Ages 18+
Boston Scientific Corporation · Sites in United States, Argentina, Australia and 13 more countries
Ages 18+
Boston Scientific Corporation · Sites in United States, Australia, Belgium and 11 more countries
Ages 18+
By country, each count listing its studies:
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2018.
This study's enrollment of 97 is above the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 46 across the 32 interventional studies, 828 across the 5 observational. Of the 29 that completed or were terminated, 26 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boston Scientific Corporation is the lead sponsor of 528 studies on the registry; 40 are open to participants now.
Of its 65 completed or terminated interventional studies of FDA-regulated products, 57 (88%) have results posted.
1 of the studies in Chronic Pain by Boston Scientific Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07190807Boston Scientific CorporationManaging Pain Using Optimized Sequences by Adjusting Parameters With Independent Current Control | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 37 studies in Chronic Pain by Boston Scientific Corporation, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To demonstrate the value of multiple modalities and sustained clinically significant pain relief in patients with chronic pain when using the Boston Scientific Spectra WaveWriter Spinal Cord Stimulator (SCS) System.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Spectra WaveWriter SCS System
Device: Spectra WaveWriter SCS System
Multiple modalities of stimulation therapy
Also known as: Spectra WaveWriter Spinal Cord Stimulation System
Percentage of Subjects With 50% or Greater Reduction in Overall Pain From Baseline
Time frame: 3 months post activation
Subjects were considered enrolled once informed consent was completed. Only those who met all eligibility criteria went on to receive implant and proceed in the study.
| Milestone | Spinal Cord Stimulation |
|---|---|
| Started | 40 |
| Completed | 37 |
| Not completed | 3 |
| Participants | Spinal Cord Stimulation |
|---|---|
| Percentage of Subjects With 50% or Greater Reduction in Overall Pain From Baseline | 31 |
Collected over Adverse Events were collected through the entire study (up to 1 year post-activation) for all enrolled subjects in the study. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Spinal Cord Stimulation | 1/97 (1%) | 7/97 (7.2%) | 0/97 (0%) |
| Event | Spinal Cord Stimulation |
|---|---|
| AnginaCardiac disorders | 1/97 |
| Myocardial InfarctionCardiac disorders | 1/97 |
| Sinus Node DysfunctionCardiac disorders | 1/97 |
| Back PainMusculoskeletal and connective tissue disorders | 1/97 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 1/97 |
| SpondylolisthesisMusculoskeletal and connective tissue disorders | 1/97 |
| Cerebrovascular AccidentNervous system disorders | 1/97 |
| Age, Continuous(years) | Spinal Cord Stimulation |
|---|---|
| Mean | 63.2 ± 12 |
| Sex: Female, Male(Participants) | Spinal Cord Stimulation |
|---|---|
| Female | 22 |
| Male | 18 |
| Race (NIH/OMB)(Participants) | Spinal Cord Stimulation |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 40 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2018 to primary completion in Jan 2019, 12 months.
Results were first posted in Mar 2020, 1 year 2 months after primary completion.
Of 83 industry-sponsored interventional studies with no phase under Chronic Pain, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 30. This study's 12 months is below that.
Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boston Scientific Corporation →